TY - JOUR
T1 - Long-term cognitive and psychosocial outcomes in adults with phenylketonuria
AU - Aitkenhead, Lynne
AU - Krishna, Gauri
AU - Ellerton, Charlotte
AU - Moinuddin, Md
AU - Matcham, Jessica
AU - Shiel, Lisha
AU - Hossain, Shasoty
AU - Kiffin, Marianne
AU - Foley, Jennifer
AU - Skeath, Rachel
AU - Cleary, Maureen
AU - Lachmann, Robin
AU - Murphy, Elaine
N1 - This article is protected by copyright. All rights reserved.
Funding Information:
This research was part‐funded by the Nutricia Metabolic Research Fund. Lynne Aitkenhead has received research and educational grants from Nutricia and Biomarin, honoraria or consulting fees from Nutricia and Vitaflo, and travel support from Biomarin. Charlotte Ellerton sits on advisory boards for Nutricia and Meta Healthcare, has received research grants from Nutricia and honoraria and travel support from Nutricia, Vitaflo, Akcea Therapeutics and SOBI. Gauri Krishna, Md Moinuddin, Jessica Matcham, Lisha Shiel, Shasoty Hossain, Marianne Kiffin and Jennifer Foley declare that they have no conflict of interest. Rachel Skeath has received payment for lectures or educational presentation from Nutricia and Vitaflo and travel support from Nutricia, Vitaflo and Mevalia. She is a member of an advisory board for Meta Healthcare. Maureen Cleary has served on a PKU advisory board for Biomarin. Robin Lachmann has received consulting fees from Biomarin and Nestle Health Sciences, and honoraria and travel support from Nutricia. Elaine Murphy has received research grants, honoraria and consulting fees from Nutricia.
Funding Information:
The authors thank all the adults with PKU and their relatives who participated in this study. The authors gratefully acknowledge the teams at Great Ormond Street Hospital Laboratory Medicine and the UCLH Neurometabolic Unit for sharing their records, particularly Helen Aitkenhead and Stuart Bennett. This research was part‐funded by the Nutricia Metabolic Research Fund and supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre and the National Institute for Health Research North Thames Clinical Research Network. The authors confirm independence from the sponsors; the content of the article has not been influenced by the sponsors.
Publisher Copyright:
© 2021 SSIEM.
PY - 2021/8/18
Y1 - 2021/8/18
N2 - Previous studies have suggested that cognitive and psychosocial underfunctioning in early-treated adults with PKU may be explained by suboptimal adherence to dietary treatments, however these studies often employ small samples, with different outcome measures, definitions and cut-offs. Samples have also tended to comprise participants with a limited range of blood phenylalanine concentrations, and often individuals who may not have been treated early enough to avoid neurological damage. In this study, we explore the impact of lifetime dietary control, as indicated by blood phenylalanine concentrations in childhood, adolescence and adulthood, on long-term cognitive and psychosocial outcomes in a large sample of adults with PKU who were diagnosed by neonatal screening and commenced on dietary treatment within the first month of life. 154 participants underwent cognitive testing, assessing attention, learning, working memory, language, executive functioning and processing speed. 149 completed measures of psychosocial functioning, documenting educational, occupational, quality of life, emotional and social outcomes which were compared with a group of healthy controls. Many adults with PKU demonstrated cognitive impairments, most frequently affecting processing speed (23%), executive function (20%) and learning (12%). Cognitive outcomes were related to measures of historic metabolic control, but only processing speed was significantly related to phenylalanine concentration at the time of testing after controlling for historic levels. Adults with PKU did not, however, differ from controls in educational, occupational, quality of life or emotional outcomes, or on a measure of family functioning, and showed only minor differences in relationship style. These findings have implications for patient counselling and decisions regarding the management of PKU in adulthood. This article is protected by copyright. All rights reserved.
AB - Previous studies have suggested that cognitive and psychosocial underfunctioning in early-treated adults with PKU may be explained by suboptimal adherence to dietary treatments, however these studies often employ small samples, with different outcome measures, definitions and cut-offs. Samples have also tended to comprise participants with a limited range of blood phenylalanine concentrations, and often individuals who may not have been treated early enough to avoid neurological damage. In this study, we explore the impact of lifetime dietary control, as indicated by blood phenylalanine concentrations in childhood, adolescence and adulthood, on long-term cognitive and psychosocial outcomes in a large sample of adults with PKU who were diagnosed by neonatal screening and commenced on dietary treatment within the first month of life. 154 participants underwent cognitive testing, assessing attention, learning, working memory, language, executive functioning and processing speed. 149 completed measures of psychosocial functioning, documenting educational, occupational, quality of life, emotional and social outcomes which were compared with a group of healthy controls. Many adults with PKU demonstrated cognitive impairments, most frequently affecting processing speed (23%), executive function (20%) and learning (12%). Cognitive outcomes were related to measures of historic metabolic control, but only processing speed was significantly related to phenylalanine concentration at the time of testing after controlling for historic levels. Adults with PKU did not, however, differ from controls in educational, occupational, quality of life or emotional outcomes, or on a measure of family functioning, and showed only minor differences in relationship style. These findings have implications for patient counselling and decisions regarding the management of PKU in adulthood. This article is protected by copyright. All rights reserved.
KW - cognition
KW - metabolic
KW - neuropsychology
KW - outcomes
KW - Phenylketonuria
KW - PKU
UR - https://www.mendeley.com/catalogue/8742f465-f1b0-3d09-b89f-0350f414808f/
UR - http://www.scopus.com/inward/record.url?scp=85112730950&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85112730950&partnerID=8YFLogxK
U2 - 10.1002/jimd.12413
DO - 10.1002/jimd.12413
M3 - Article (journal)
C2 - 34145605
SN - 0141-8955
JO - Journal of Inherited Metabolic Disease
JF - Journal of Inherited Metabolic Disease
ER -